New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Global ETF Survey 2026
›ETF Issuers›L&G›BIGT
BIGT

L&G Pharma Breakthrough UCITS ETF

The BIGT Exchange Traded Fund (ETF) is provided by L&G. It is built to track an index: Solactive Pharma Breakthrough Value Index. The BIGT ETF provides physical exposure, so by buying it you actually own parts of all the 36 underlying holdings. The dividend policy is capitalization.

Advertisement

Advertisement

£1,099.60
+£3.4 (+0.31%) today
7:00 AM 07/17/26 Closed
1D price range
£1,084.20£1,113.20
52W price range
£10.96£15.73
YTD Perf.
+7.84%
YTD Flows
Annualized volatility
Fund AuM
€19M
Share class AuM
€19M
TTM Yield
-
Tracking Error
Tracking Difference
ISIN
IE00BF0H7608
TER
0.49%
Inception date
1/23/2018
Issuer
Replication method
Dividend policy
Compare similar ETFs
API
PerformanceDec 31, 2025 - Jul 16, 2026
-5%0%5%10%15%JANMARMAYJUL
Flows
Join for free to unlock
Data as of 05/31/26
Healthcare
97.15%
Industrials
2.77%
Latest BIGT news

No content available for this fund

FAQ about BIGT

BIGT is a Passive ETF. This ETF provides exposure to Other Equities.
BIGT tracks the Solactive Pharma Breakthrough Value NTR Index - USD, through a full replication replication method.
BIGT carries a total expense ratio (TER) of 0.49%, indicating the annual cost for holding the fund.
BIGT was introduced to the market on January 23, 2018. It trades on Spain, among other exchanges
L&G Pharma Breakthrough UCITS ETF, BIGT, is provided by L&G. Learn more about L&G here.
BIGT oversees €19M in assets as of July 16, 2026.
BIGT follows a capitalizing, meaning it reinvests income within the fund.
As of May 31, 2026, BIGT has significant geographic allocations in USA, Japan and Switzerland.
As of May 31, 2026, BIGT focuses largely on Healthcare and Industrials.
As of May 31, 2026, BIGT holds 36 positions in its portfolio, with 46.54% of assets concentrated in its top 15 holdings.
As of May 31, 2026, BIGT top three holdings include Travere Therapeutics, Inc., Jazz Pharmaceuticals Plc and Pharma Mar SA.
The base currency of BIGT is USD.
Data as of 05/31/26
Travere Therapeutics, Inc.
4.28%
Jazz Pharmaceuticals Plc
3.47%
Pharma Mar SA
3.31%
United Therapeutics Corp.
3.18%
Royalty Pharma Plc
3.12%
Ligand Pharmaceuticals, Inc.
3.07%
Swedish Orphan Biovitrum AB
3.03%
Zevra Therapeutics, Inc.
3.02%
Mirum Pharmaceuticals, Inc.
3.01%
argenx SE
2.97%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight